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Abstract
Purpose Sunitinib in combination with docetaxel enhan-
ces antitumor activity in xenograft models of human breast
and non-small cell lung cancer. We assessed the maximum
tolerated doses (MTDs), safety, pharmacokinetic proﬁles,
and preliminary efﬁcacy of sunitinib plus docetaxel in
patients with advanced solid tumors.
Methods In this phase I study, successive patient cohorts
received sunitinib 25, 37.5, or 50 mg/day for 4 weeks of a
6-week cycle (Schedule 4/2, 4 weeks on, 2 weeks off) or
for 2 weeks of a 3-week cycle (Schedule 2/1, 2 weeks on,
1 week off) with docetaxel 60 or 75 mg/m
2 IV q21d to
determine the MTDs of this treatment combination.
Results Fifty patients enrolled: 10 on Schedule 4/2 and 40
on Schedule 2/1. MTDs were established as sunitinib
25 mg on Schedule 4/2 with docetaxel 60 mg/m
2 q21d, and
as sunitinib 37.5 mg on Schedule 2/1 with docetaxel
75 mg/m
2 q21d. On Schedule 2/1, the most frequent dose-
limiting toxicity was neutropenia (±fever; grade [G]3/4,
n = 5) and the most common G3/4 non-hematologic
adverse event (AE) was fatigue (G3, n = 8). Hematologic
AEs were managed with growth factor support in 11 of 23
(48%) patients treated at Schedule 2/1 MTD. Three patients
achieved a partial response at the Schedule 2/1 MTD.
There were no pharmacokinetic drug–drug interactions
with either schedule.
Conclusions Oral sunitinib 37.5 mg/day on Schedule 2/1
with docetaxel 75 mg/m
2 IV q21d is a clinically feasible
regimen with a manageable safety proﬁle, no pharmaco-
kinetic drug–drug interactions, and shows antitumor
activity in patients with advanced solid tumors.
Keywords Sunitinib  Docetaxel  Solid tumors 
Phase I  NSCLC  Antiangiogenesis
Introduction
Advances in the molecular biology of solid malignancies
have established the critical role of tumor angiogenesis and
the multiple signaling pathways involved in tumor devel-
opment. Speciﬁcally, inhibition of the vascular endothelial
growth factor (VEGF) pathway has been shown to improve
clinical efﬁcacy outcomes in patients with a variety of
cancers [1–5]. There is interest in assessing the efﬁcacy and
safety of targeted agents given in combination with che-
motherapy, including in patients with treatment-refractory
cancers.
Docetaxel (Taxotere
, Sanoﬁ Aventis, US) is an effec-
tive anticancer therapy which stabilizes microtubules,
leading to the formation of abnormal microtubule bundles
that prevent mitotic processes [6, 7]. Its major dose-limit-
ing toxicity (DLT) is reversible myelosuppression. In the
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DOI 10.1007/s00280-009-1209-0US, docetaxel is indicated both as a single agent and in
combination with other agents for various solid tumors
including non-small cell lung cancer (NSCLC) and breast
cancer [7].
Sunitinib malate (SUTENT
, Pﬁzer Inc. US) is an oral
multitargeted tyrosine kinase inhibitor (TKI), approved
internationally for use in advanced renal cell carcinoma
(RCC) and imatinib-resistant or -intolerant gastrointestinal
stromal tumor (GIST), based on its demonstrated clinical
activity and tolerability proﬁle [8–10]. Sunitinib inhibits
VEGF and platelet-derived growth factor (PDGF) receptor
subtypes, stem cell factor receptor (KIT), FMS-like tyro-
sine kinase (FLT3), glial cell line-derived neurotrophic
factor (REarranged during Transfection [RET]), and col-
ony-stimulating factor 1 receptor (CSF-1R) [11–16]. Sun-
itinib has also shown clinically relevant antitumor activity
in patients with other types of advanced solid tumors in
phase I and phase II trials, including breast cancer,
NSCLC, and neuroendocrine tumor [16–20]. Common
drug-related toxicities associated with sunitinib are typi-
cally grade 1 or 2 in severity and are generally constitu-
tional (fatigue, anorexia, headache), gastrointestinal
(diarrhea, nausea, stomatitis, dyspepsia, vomiting, mucosal
inﬂammation, constipation), or cutaneous (skin discolor-
ation, rash, hand–foot syndrome, hair color changes) [16].
When given in combination, sunitinib enhances the
antitumor activity of docetaxel in nonclinical studies. In
H460 mouse xenograft models of NSCLC and MX-1
mouse xenograft models of breast cancer, the addition of
sunitinib to docetaxel leads to signiﬁcant delay of tumor
regrowth compared with docetaxel alone [21, 22]. These
data suggest that the combination of sunitinib with doce-
taxel may result in greater efﬁcacy than docetaxel alone.
This phase I dose-ﬁnding study investigated the safety,
pharmacokinetics (PK), and efﬁcacy of sunitinib in com-
bination with docetaxel in patients with advanced solid
tumors.
Materials and methods
Patient eligibility
Male and female patients who were 18 years of age or
older, had histologically proven advanced solid tumors for
which curative therapy was not available, and were con-
sidered eligible for treatment with standard doses of single-
agent docetaxel were recruited. All patients provided
written and informed consent. Other key inclusion criteria
included (a) Eastern Cooperative Oncology Group (ECOG)
performance status of 0 or 1; (b) resolution of all
acute toxic effects of prior chemotherapy, radiotherapy, or
surgical procedure to National Cancer Institute Common
Terminology Criteria for Adverse Events (NCI CTCAE)
grade B 1; (c) adequate hematologic parameters (absolute
neutrophil count [ANC] C1,500/lL; platelets C100,000/
lL; hemoglobin C9 g/dL) and hepatic, renal, and cardiac
function, including left ventricular ejection fraction
(LVEF) C50% without the support of cardiotropic agents.
Exclusion criteria included (a) prior treatment with high-
dose chemotherapy requiring stem cell rescue or prior
irradiation to C25% of the bone marrow; (b) surgery,
systemic therapy or any investigational agent within
4 weeks prior to starting study treatment; (c) extensive
prior anthracycline or anthracenedione exposure (i.e.
cumulative doxorubicin exposure[300 mg/m
2, epirubicin
exposure[900 mg/m
2, mitoxanthrone exposure[120 mg/
m
2, doxorubicin liposome injection exposure [550 mg/
m
2); (d) centrally located lung lesions (unless irradiated
with C30 Gy[2 weeks prior to starting study treatment);
(e) NCI CTCAE grade 3 hemorrhage within 4 weeks of
study entry, signiﬁcant hemoptysis, or grade C 2 neurop-
athy or edema; (f) diagnosis of a second malignancy within
the last 5 years, except for adequately treated basal or
squamous cell skin cancer, localized prostate cancer, or in
situ bladder or cervical cancer; (g) known brain metastases,
spinal cord compression or carcinomatous meningitis, or
new evidence of brain or leptomeningeal disease; (h)
severe/unstable angina, symptomatic congestive heart
failure, cerebrovascular accident or transient ischemic
attack within 12 months of study entry or ongoing cardiac
dysrhythmias (grade C 2), atrial ﬁbrillation or QTc interval
prolongation; (i) history of severe hypersensitivity reaction
to docetaxel or other drugs formulated with polysorbate 80.
Patients who were pregnant or breastfeeding were also
excluded.
Study design and treatment
In this phase I, open-label, multicenter, non-randomized,
dose-ﬁnding study, successive cohorts of patients received
IV docetaxel q21d in combination with escalating daily
doses of oral sunitinib.
Sunitinib was administered using one of two dosing
schedules over approximately 18 weeks: 4 consecutive
weeks of once-daily treatment followed by 2 weeks off
treatment (Schedule 4/2) in three repeated 6-week cycles, or
2 consecutive weeks of once-daily treatment followed by 1-
week off treatment (Schedule 2/1) in six repeated 3-
week cycles. To enable sampling for PK proﬁles, on
Schedule 4/2, patients were administered sunitinib once
daily on days 4–31 in cycle 1. Patients were administered
sunitinib daily on days 1–28 in subsequent cycles. On
Schedule 2/1, patients were administered sunitinib daily on
days 1–14 with the exception of patients undergoing full-
proﬁle PK assessments; these patients were administered
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123sunitinib on days 3–16. In subsequent cycles, sunitinib was
administered daily on days 1–14. To ensure patient safety,
the starting dose level was sunitinib at 25 mg/day (50% of
its previously determined maximum tolerated dose [MTD]
as monotherapy on Schedule 4/2) with docetaxel at 60 mg/
m
2 q21d (the lowest dose recommended in the United States
package insert). MTD was deﬁned as the highest dose at
which 0/3 or 1/6 patients experienced a DLT (protocol-
deﬁned as grade 3 or 4 non-hematologic toxicity lasting
C7 days, or grade 4 neutropenia C7 days, febrile neutro-
penia [fever [38.5C for C24 h], neutropenic infection,
and/or grade C 3 thrombocytopenia with bleeding or last-
ing C7 days) during the ﬁrst 31 or 21 days of cycle 1
(Schedules 4/2 and 2/1, respectively), with the next highest
dose having C2/3 or C2/6 patients experiencing a DLT.
Additional patients were enrolled at the MTD to further
characterize safety and tolerability at this dose level.
Escalating doses of sunitinib and docetaxel were ﬁrst
studied on Schedule 4/2, starting at dose level 0 (Table 1).
Following determination of Schedule 4/2 MTD, subsequent
patients were enrolled onto Schedule 2/1, starting at the
Schedule 4/2 MTD. Dose escalation and de-escalation
occurred as detailed in Table 1 in order to determine the
MTD on Schedule 2/1. Initial cohorts of 3 patients were
enrolled onto Schedule 4/2, and any cohort was expanded
to 6 patients if a DLT was observed. An additional 3
patients could be included at speciﬁc dose levels to further
explore the observed toxicity proﬁle.
Patients were treated for the entire study period unless
there was disease progression, lack of tolerance, or with-
drawal of consent. Dose reductions by one or two dose
levels of either or both study drugs were permitted after
completion of the DLT observation period. After com-
pleting the study period, patients who were receiving
clinical beneﬁt were offered participation in an extended-
use protocol of single-agent sunitinib.
The study was performed with institutional ethics
committee approval, and in accordance with International
Conference on Harmonization Good Clinical Practice
guidelines, the Declaration of Helsinki (1996 Version), and
applicable local regulatory requirements and laws.
Study endpoints and assessments
The primary objective of this trial was to assess the MTD
and overall safety of sunitinib in combination with doce-
taxel when sunitinib was administered on Schedule 4/2 or
2/1 in patients with solid tumors. Secondary objectives
were to evaluate PK proﬁles and the efﬁcacy of this
treatment combination.
Safety was assessed by recording adverse events (AEs)
documented from the ﬁrst day of study medication (doce-
taxel or sunitinib) and graded using NCI CTCAE, version
3.0. Other safety assessments included urinalysis at
screening, hematology and blood chemistry parameters, and
physical examinations. Twelve-lead electrocardiograms
Table 1 Sunitinib and docetaxel dosing schedules, and dose-limiting toxicities
Docetaxel (every 21 days)
(mg/m
2)
Sunitinib (once-daily dose)
(mg)
Patients (N) DLTs (n/N)
Schedule 4/2
Dose level 0
a 60 25 4 None
Dose level 1 60 37.5 6 Grade 3 muscular weakness (n = 1)
Grade 3 febrile neutropenia (n = 1)
Schedule 2/1
b
Dose level 0
a 60 25 9 Grade 4 febrile neutropenia (n = 1)
Grade 4 neutropenia (n = 1)
Dose level 1 60 37.5 3 None
Dose level 2 60 50 3 None
Dose level 3a 75 50 2 Grade 3 febrile neutropenia (n = 1)
Grade 4 neutropenia (n = 1)
Dose level 3b
c 75 37.5 23 Grade 3 gastrointestinal hemorrhage (n = 1)
Grade 4 febrile neutropenia (n = 1)
MTDs were Schedule 4/2: sunitinib 25 mg/day ? docetaxel 60 mg/m
2 q21d; Schedule 2/1: 37.5 mg/day ? docetaxel 75 mg/m
2 q21d
a Initial dose used
b Following completion of Schedule 4/2 dose determination (18 weeks on study), subsequent patients were enrolled onto Schedule 2/1, starting
at Schedule 4/2 MTD
c Six patients were originally enrolled at this dose level with one DLT (grade 3 gastrointestinal hemorrhage) observed. The cohort was expanded
to include 17 additional patients to further characterize the safety and tolerability of this dose level
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123(ECG) and multigated acquisition (MUGA) scans were
performed at screening and during treatment (cycles 1 and
3, respectively for Schedule 4/2, and cycles 2 and 6,
respectively for Schedule 2/1).
Objective tumor response was assessed in patients with
measurable disease according to Response Evaluation
Criteria in Solid Tumors (RECIST) [23]. Radiologic tumor
assessments were performed at screening, during treatment
(during cycles 1 and 2 for Schedule 4/2, and cycles 2 and 4
for Schedule 2/1), at the end of the dosing period (if not
performed within the previous 6 weeks), whenever disease
progression was suspected and to conﬁrm response (at least
4 weeks after initial evidence of response).
Full PK proﬁles for docetaxel and sunitinib were obtained
for all patients on Schedule 4/2 and those patients enrolled on
the MTD expansion cohort on Schedule 2/1. PK parameters
for sunitinib, its primary metabolite (SU12662), total drug
(sunitinib ? SU12662), and docetaxel arereported as well as
trough levels.Full PK proﬁlesfordocetaxel were obtained on
days1and22ofcycle1onSchedule4/2andonday1ofcycles
1 and 2 on Schedule 2/1, using blood samples collected pre-
d o s ea n d0 . 5 ,1 ,1 . 5 ,2 ,3 ,4 ,6 ,8 ,1 2 ,a n d2 4hp o s t - d o c e t a x e l
dose. Docetaxel PK parameters were analyzed at Covance
Laboratories (Madison, WI) using a validated liquid chro-
matographic–tandem mass spectrometric method in accor-
dancewithCovance’sSOPs.FullPKproﬁlesforsunitiniband
SU12662 were obtained on days 18 and 22 on Schedule 4/2
and onday 3 ofcycle 1,and day 1 ofcycle 2 onSchedule 2/1.
Blood samples were collected pre-dose, and 1, 2, 4, 6, 8, 12,
and24 hpost-sunitinibdose.Additionaltroughbloodsamples
werecollectedforpatientsonSchedule4/2oncycles2/3 days
1 and 28 (day 31 of cycle 1 only) and on Schedule 2/1 on
cycles 1–6 day 1 and day 14 of cycle 1. Sunitinib PK
parameters were analyzed at Bioanalytical Systems Inc
(BASi, West Lafayette, IN) using a validated liquid chro-
matographic–tandem mass spectrometric method in accor-
dance with BASi’s standard operating procedures (SOPs).
Statistical methods
Maximum enrollment into the trial was dependent upon the
observed safety proﬁle, which determined the number of
patients per dose level and number of dose escalations. The
populations for safety analyses included all patients who
had taken at least one dose of study medication. Efﬁcacy
analyses were performed on patients with measurable dis-
ease at baseline who received at least one dose of sunitinib
and had a response assessment made by the investigator.
Descriptive statistics were used to summarize all patient
characteristics, safety parameters, efﬁcacy endpoints, and
PK parameters. PK parameters were calculated for each
subject by noncompartmental analysis using WinNonlin
Version 4.1a. Samples below the limit of quantitation were
includedaszero.Ifpre-doseconcentrationsofastudydrugor
metabolite for an individual were[5% of Cmax, a dose cor-
rection was made. Only patients with paired observations at
eachdoselevel were includedindescriptivestatisticsforPK
proﬁlesofsunitinib,SU12662,totaldrug,anddocetaxel,and
for comparison of PK parameters when sunitinib or doce-
taxelwasadministeredaloneorincombination.Troughdata
are reported for all patients with trough observations.
Results
Patient characteristics
Intotal,50patientswereenrolledintothetrial;10patientsand
40patientsreceivedsunitinibonSchedule4/2andSchedule2/
1, respectively. Patient characteristics at baseline are sum-
marized in Table 2. NSCLC (Schedule 4/2: n = 1, 10%;
Schedule 2/1: n = 17, 43%) and RCC (Schedule 4/2: n = 7,
70%;Schedule2/1:n = 3,8%)werethemostcommontumor
types. All patients had undergone previous cancer-related
surgery, and most had received previous systemic therapy
(Schedule 4/2: n = 10, 100%; Schedule 2/1 n = 32, 80%).
Five (50%) and 11 (28%) patients had undergone previous
radiotherapy on Schedules 4/2 and 2/1, respectively.
On Schedule 4/2, the median number of treatment cycles
started was two (range 1–3). Thirty percent (n = 3) of
sunitinib treatment interruptions were due to AEs
(Table 3). Of the 10 patients on Schedule 4/2, 5, 2, and 3
patients received 1, 2, and 3 cycles of sunitinib treatment,
respectively. On Schedule 2/1, the median number of
treatment cycles started was four (range 1–6). The 28%
(n = 11) of sunitinib treatment interruptions were all due
to AEs (Table 3). Of the 40 patients on Schedule 2/1, 8, 7,
and 2 patients started 1, 2, and 3 cycles of sunitinib treat-
ment, respectively, and 8, 3, and 12 patients started 4, 5,
and 6 cycles of sunitinib treatment, respectively.
Six patients (60%) discontinued treatment on Schedule
4/2 due to AEs, including dyspnea; muscular weakness and
hypoesthesia; infection; atrial ﬁbrillation and thrombosis;
obstructive airways disorder; and pain, nausea, and vom-
iting in 1 patient each. Five patients (13%) discontinued
treatment on Schedule 2/1 due to AEs, which included
disease progression (3 patients); pyrexia and infection (1
patient); and fatigue, anorexia, leukopenia, neutropenia,
dehydration, and diarrhea (1 patient).
Safety and tolerability
Schedule 4/2
Determination of MTD MTD was determined as sunitinib
25 mg/day on Schedule 4/2 plus docetaxel 60 mg/m
2 q21d
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123(dose level 0, n = 4); no DLTs were observed at this dose
level. DLTs at dose level 1 (sunitinib 37.5 mg/day, doce-
taxel 60 mg/m
2 q21d, n = 6) were grade 3 muscular
weakness, which led to discontinuation of study treatment,
and grade 3 febrile neutropenia.
Other safety ﬁndings The most frequently reported
treatment-emergent (all-causality) non-hematologic AEs in
patients treated on Schedule 4/2 were typically grade 1 or
2. Common toxicities were generally constitutional (fati-
gue, pyrexia, mucosal inﬂammation, anorexia), gastroin-
testinal (diarrhea, nausea, vomiting, stomatitis), or
cutaneous (rash and alopecia).
Grade 3/4 treatment-emergent AEs included neutropenia
(6 patients), hypophosphatemia (4 patients), febrile neutrope-
nia (3 patients), fatigue (2 patients), and nausea, infection,
hemoglobin decrease and hyperglycemia, in 1 patient each
(Table 4). At the MTD, 1 patient developed grade 4 febrile
neutropenia and began receiving pegﬁlgrastim on day 41 of
cycle 1 (this event was not considered a DLT as it began after
day 31 of cycle 1). Serial ECG and MUGA scans were avail-
ablefor8and4of 10patients,respectively.Nopatienttreated
on Schedule 4/2 experienced LVEF declines by C20% to
below the lower limit of normal or grade[1i n c r e a s ei nQ T c
interval. One patient on Schedule 4/2 died during the study
(disease progression considered not related to study drug).
Table 2 Patient characteristics at baseline
Schedule 4/2 (N = 10) Schedule 2/1
All patients (N = 40) MTD
a only (n = 23)
Age in years
Median (range) 57 (46–72) 56 (26–74) 55 (37–73)
\65, n (%) 7 (70) 33 (83) 18 (78)
C65, n (%) 3 (30) 7 (18) 5 (22)
Sex, n (%)
Male 8 (80) 20 (50) 7 (30)
Female 2 (20) 20 (50) 16 (70)
ECOG performance status, n (%)
0 2 (20) 8 (20) 4 (17)
1 8 (80) 32 (80) 19 (83)
Primary tumor types, n (%)
RCC 7 (70) 3 (8) 0
NSCLC 1 (10) 17 (43) 11 (48)
Adenocarcinoma 0 7 (18) 3 (13)
Squamous cell carcinoma 0 3 (8) 2 (9)
Bronchioloalveolar carcinoma 0 1 (3) 1 (4)
Other/NOS 1 (10) 6 (15) 5 (22)
Other tumor type
b 2 (20) 20 (50) 12 (52)
Previous cancer-related surgery 10 (100) 40 (100) 23 (100)
Outcome
Partial/complete resection 1 (10)/6 (60) 2 (5)/19 (48) 1 (4)/9 (39)
Not applicable 3 (30) 19 (48) 13 (57)
Previous radiotherapy 5 (50) 11 (28) 6 (26)
Previous systemic therapy 10 (100) 32 (80) 17 (74)
Number prior systemic therapies
1 2 (20) 6 (15) 3 (13)
C2 8 (80) 26 (65) 14 (61)
ECOG Eastern cooperative oncology group, NOS not otherwise speciﬁed, NSCLC non-small cell lung carcinoma, RCC renal cell carcinoma
a 2/1 MTD = sunitinib 37.5 mg/day ? docetaxel 75 mg/m
2 q21d
b Other primary tumor type includes: esophageal carcinoma, metastatic melanoma, adenocystic-salivary gland (metastatic), carcinoid tumor of
colon and appendix, ductal carcinoma in situ (breast), gastric adenocarcinoma, malignant mesothelioma, metastatic osteosarcoma, metastatic
adenocystic carcinoma (vulva), metastatic pulmonary carcinoid tumor, metastatic soft tissue sarcoma, neuroendocrine, pancreas, prostate, rectal
carcinoma, retroperitoneal leiomyosarcoma, small cell lung cancer, and well-differentiated neuroendocrine carcinoma
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123Because the established MTD on Schedule 4/2 (sunitinib
25 mg/day plus docetaxel 60 mg/m
2 q21d) was considered
sub-optimal for both agents and inconvenient for admin-
istration, this schedule was not pursued any further.
Schedule 2/1
Determination of MTD On Schedule 2/1, 2 of 6 patients
experienced a DLT (grade 4 neutropenia, grade 4 febrile
neutropenia) on sunitinib 25 mg/day plus docetaxel 60 mg/
m
2 q21d (dose level 0), the ﬁrst dose level tested on
Schedule 2/1. However, since this regimen was tolerable
on Schedule 4/2 (where sunitinib was received for 28 days
compared with 14 days on Schedule 2/1), the study was
amended to enroll an additional 3 patients at this dose level
to further explore the toxicity proﬁle. No further DLTs
occurred and dose escalation proceeded. Three patients
were treated at each of the next two dose levels (sunitinib
37.5 mg/day plus docetaxel 60 mg/m
2 q21d [dose level 1],
sunitinib 50 mg/day plus docetaxel 60 mg/m
2 q21d [dose
Table 3 Patient disposition
Schedule 4/2 dose
levels
a 0–1 (N = 10)
Schedule 2/1 dose levels
a 0–3b
All patients
(N = 40)
MTD only dose
level 3b (n = 23)
Median cycles started (range) 2 (1–3) 4 (1–6) 4 (1–6)
Treatment interruption for sunitinib, n (%)
Adverse event 3 (30) 11 (28) 9 (39)
Other 0 0 0
Dose reduction for sunitinib, n (%) 1 (10) 5 (13) 4 (17)
Reason for treatment discontinuation, n (%)
Adverse event 6 (60) 5 (13) 4 (17)
Consent withdrawn 1 (10) 2 (5) 1 (4)
Lack of antitumor activity 2 (20) 16 (40) 8 (35)
Sponsor decision 0 3
b (8) 1 (4)
Patient completed study per protocol 1 (10) 14 (35) 9 (39)
a Dose level 0 = sunitinib 25 mg ? docetaxel 60 mg/m
2 q21d (initial dose level used); dose level 1 = sunitinib 37.5 mg ? docetaxel 60 mg/
m
2 q21d; dose level 2 = sunitinib 50 mg ? docetaxel 60 mg/m
2 q21d; dose level 3a = sunitinib 50 mg ? docetaxel 75 mg/m
2 q21d; dose level
3b = sunitinib 37.5 mg ? docetaxel 75 mg/m
2 q21d
b These patients were discontinued from this study and enrolled in a different study of single-agent sunitinib. Two patients discontinued
docetaxel due to adverse events. One patient was discontinued due to a concomitant illness
Table 4 All-causality grade 3/4
adverse events (n, %), all cycles
and occurring in C2 patients
across both treatment schedules
GI Gastrointestinal; NOS not
otherwise speciﬁed
Adverse event Schedule 4/2 (N = 10) Schedule 2/1 (N = 40)
Grade 3
n (%)
Grade 4
n (%)
Grade 3
n (%)
Grade 4
n (%)
Neutropenia 1 (10.0) 5 (50.0) 4 (10.0) 20 (50.0)
Fatigue 2 (20.0) 0 8 (20.0) 0
Febrile neutropenia 2 (20.0) 1 (10.0) 1 (2.5) 3 (7.5)
Hyperglycemia 1 (10.0) 0 4 (10.0) 0
Hypophosphatemia 4 (40) 0 0 0
Leukopenia 0 0 3 (7.5) 1 (2.5)
Hypokalaemia 0 0 3 (7.5) 0
Dyspnea 0 0 1 (2.5) 1 (2.5)
Diarrhea 0 0 3 (7.5) 0
Hemaglobin decrease 1 (10.0) 0 1 (2.5) 0
Hypersensitivity 0 0 2 (5.0) 0
Infection (NOS) 1 (10.0) 0 1 (2.5) 0
Nausea 1 (10.0) 0 1 (2.5) 0
Pyrexia 0 0 2 (5.0) 0
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123level 2]), and no DLTs were observed. Both patients
treated with sunitinib 50 mg plus docetaxel 75 mg/m
2 q21d
(dose level 3) experienced DLTs (grade 3 febrile neutro-
penia and grade 4 neutropenia); therefore a lower dose
level was tested (dose level 3b: sunitinib 37.5 mg/day plus
docetaxel 75 mg/m
2 q21d). At this dose level, 1 of 6
patients experienced a DLT (grade 3 gastrointestinal
hemorrhage), and sunitinib 37.5 mg/day on Schedule 2/1
plus docetaxel 75 mg/m
2 q21d was determined to be the
MTD. Seventeen additional patients were enrolled at
Schedule 2/1 MTD to further characterize the safety, tol-
erability, and antitumor effects of the treatment combina-
tion, and to obtain full PK proﬁles on sufﬁcient patients (a
total of 23 patients were enrolled at Schedule 2/1 MTD).
Of these 17 additional patients, 1 experienced a DLT
(grade 4 febrile neutropenia).
Other safety ﬁndings Fatigue (70%), diarrhea (57%), and
pyrexia (57%) were the most frequently reported treat-
ment-emergent (all-causality) non-hematologic AEs in
patients treated at the MTD on Schedule 2/1. Most of these
AEs were mild or moderate in severity (grade 1 or 2). The
most common grade 3 treatment-emergent non-hemato-
logic AEs in patients treated at the MTD were fatigue
(22%), hyperglycemia (13%), hypokalemia (13%), diar-
rhea, and pyrexia (both 9%) (Table 5). Grade 4 non-
hematologic AEs occurring at the MTD on Schedule 2/1
were hyperuricemia and atrophic vulvovaginitis (both
n = 1 [4%]). There were no notable differences in types
and severity of AEs in the MTD group compared with all
subjects on Schedule 2/1.
Grade 4 hematologic laboratory abnormalities in the 23
patients treated at the MTD on Schedule 2/1 were neutro-
penia, n = 15 (65%), febrile neutropenia n = 2 (9%), and
leukopenia,n = 1(4%).AcrossallSchedule2/1doselevels,
neutropenia (any grade) was attributable to sunitinib and to
docetaxel in 19/40 (48%) and 24/40 (60%) patients, respec-
tively, (in 3 subjects, neutropenia was attributed to both
drugs). Across all Schedule 2/1 dose levels, febrile
neutropenia of any grade was attributable to sunitinib and to
docetaxel in 5/40 (13%) and 4/40 (10%) patients, respec-
tively. Overall, 14 patients received granulocytic growth
factor support on Schedule 2/1, including 11 (48%) in the
MTD cohort; growth factors used most commonly were
pegﬁlgrastim,andﬁlgrastimweregivenduringcycles2,3,or
4 of the study treatment. Despite the use of growth factor
support, the incidence of grade 3/4 febrile neutropenia was
13% in the MTD cohort. Erythropoeitic growth factors
administeredincludederythropoietin(n = 3[8%]andn = 1
[4%]),darbepoetinalfa(n = 4[10%]andn = 4[17%]),and
epoetin alfa (n = 2 [5%] and n = 1 [4%]) on Schedule 2/1
overall and the MTD cohort, respectively. In addition, 1
patient on the MTD cohort received packed red blood cells.
Of the subjects receiving prophylactic growth factors, 3
(6%) on Schedule 2/1 were receiving growth factors
(erythropoietin, n = 3) for pre-existing anemia before
beginning treatment with sunitinib/docetaxel. Two patients
on Schedule 2/1 (6%) began receiving growth factors during
cycle 1: One patient (sunitinib 25 mg plus docetaxel 60 mg/
m
2)began receivingpegﬁlgrastim onday12ofcycle1,after
experiencing grade 4 febrile neutropenia; this event was
considered a DLT. The second patient (sunitinib 37.5 mg
plus docetaxel 75 mg/m
2) began pegﬁlgrastim on day 10 of
cycle 1, after experiencing grade 4 neutropenia; this event
was not considered a DLT as it resolved in 4 days.
The subject who experienced the grade 3 DLT of gas-
trointestinal hemorrhage on the Schedule 2/1 MTD was a
38-year-old white female with neuroendocrine tumor
diagnosed 6 years earlier and previously treated with
pancreatectomy, splenectomy, external beam radiation to
the pancreas, 5-ﬂuorouracil, octreotide, geﬁtinib, cisplatin/
etoposide, and two experimental study medications. The
subject entered the study with liver and lung metastases,
pleural effusion, and ascites. On day 13 of cycle 1,she was
admitted to the hospital and treated for an ileus and dis-
charged the following day. The subject returned to clinic
on day 20 of cycle 1 and reported black, tarry stools;
endoscopy revealed severe esophagitis, which was treated
Table 5 All-causality adverse
events including all grades (n,
%) in all cycles and occurring in
C2 patients (grade 3/4) for
Schedule 2/1 at the MTD
(sunitinib 37.5 mg ? docetaxel
75 mg/m
2 q21d)
Adverse event Schedule 2/1 MTD (N = 23)
Grade 1
n (%)
Grade 2
n (%)
Grade 3
n (%)
Grade 4
n (%)
Neutropenia 0 2 (8.7) 0 15 (65.2)
Fatigue 4 (17.4) 7 (30.4) 5 (21.7) 0
Febrile neutropenia 0 0 1 (4.3) 2 (8.7)
Hyperglycemia 1 (4.3) 4 (17.4) 3 (13.0) 0
Leukopenia 0 1 (4.3) 1 (4.3) 1 (4.3)
Hypokalaemia 0 0 3 (13.0) 0
Diarrhea 5 (21.7) 6 (26.1) 2 (8.7) 0
Pyrexia 7 (30.4) 4 (17.4) 2 (8.7) 0
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123with esomeprazole and blood transfusion. This DLT
resolved with dose delay/reduction of the study drug and
gastrointestinal hemorrhage recurred 4 weeks later at grade
1, resolving without action.
Serial ECGs were available for 25 of 40 patients and
MUGA scans were available for 22 of 40 patients,
respectively. No patients experienced LVEF declines by
C20% to below the lower limit of normal or grade[1
increase in QTc interval. Hand–foot syndrome occurred in
10% of patients on Schedule 2/1, with one patient experi-
encing a grade 3 event. Four patients on Schedule 2/1 died
during the study; three deaths were reported during the
study, and one was reported after the follow-up period. All
deaths were considered to be due to disease progression
and were not attributed to the study medication.
Pharmacokinetics Mean sunitinib and docetaxel concen-
tration data showed overlapping proﬁles during cycles 1
(docetaxel alone) and 2 (docetaxel plus sunitinib) (Fig. 1).
These patients were administered sunitinib starting on day
3. Plasma PK parameter values and geometric mean ratios
for patients with paired observations for sunitinib,
SU12662, total drug, and docetaxel, following multiple
dosing with sunitinib alone and with docetaxel, are sum-
marized in Table 6a and b, respectively. For subjects
treated on Schedule 2/1 at the MTD, the respective
geometric mean ratios (i.e. sunitinib ? docetaxel to suni-
tinib alone) of Cmax and AUC24 were 1.09 and 1.05 for
sunitinib, 1.16 and 0.99 for SU12662, and 1.10 and 1.06 for
total drug. The mean trough plasma concentration for day
14 of cycle 1 was 43.8 ng/mL for sunitinib, 16.4 ng/mL for
SU12662, and 60.1 ng/mL for total drug. The PK param-
eters for sunitinib (37.5 mg) and docetaxel (60 mg/m
2)o n
Schedules 4/2 dose level 1 and 2/1 dose level 3b in this
study are consistent with other studies at this dose level of
sunitinib. PK samples for sunitinib were collected at a
steady state after 18 or 22 days of treatment on Schedule 4/
2 compared with at the beginning of each cycle (after
7 days of wash out time when sunitinib level is very low)
on Schedule 2/1, and therefore PK parameters differed.
Efﬁcacy assessments Nine patients on Schedule 4/2 were
evaluable for efﬁcacy: 4 patients (44%) achieved stable
disease (SD) and 2 patients (22%) experienced progressive
disease (PD). Response data for 3 patients were not
evaluable (no post-baseline measurements available).
Thirty-eight patients on Schedule 2/1 were evaluable for
efﬁcacy. Three patients (13%) treated at MTD achieved a
partial response (PR) and had the following primary tumor
types and characteristics (all had multiple metastases):
invasive adenocarcinoma of the breast (67-year-old white
female who had prior surgery but no prior radiotherapy or
Fig. 1 Mean a sunitinib and b
docetaxel plasma dose corrected
linear and log–linear
concentration versus time
proﬁles for patients who
received MTD (37.5 mg
sunitinib plus 75 mg/m
2
docetaxel) on Schedule 2/1
a
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123Table 6 PK parameters for study drugs (patients with paired observations only)
Mean (SD)
sunitinib alone
Mean (SD)
docetaxel ? sunitinib
Geometric mean ratio
(combination/drug alone)
(a) Sunitinib, SU12662,
c and total drug
d
Schedule 4/2
Dose level 0, n = 3
Sunitinib
AUC0–24 (ng*h/mL) 721.2 (289.0) 548.0 (164.7) 0.78
Cmax (ng/mL) 36.4 (15.7) 27.8 (7.4) 0.79
Tmax (h)
a 6.0 (4.0, 6.0) 4.0 (4.0, 4.0) NA
SU12662
AUC0–24 (ng*h/mL) 294.0 (195.0) 299.9 (132.7) 1.10
Cmax (ng/mL) 13.3 (8.3) 14.4 (7.2) 1.14
Tmax (h)
a 4.0 (4.0, 12.0) 4.0 (2.0, 4.0) NA
Total drug
AUC0–24 (ng*h/mL) 1,015.5 (478.7) 848.3 (288.7) 0.86
Cmax (ng/mL) 49.1 (23.8) 42.1 (14.2) 0.89
Tmax (h)
a 4.0 (4.0, 6.0) 4.0 (4.0, 4.0) NA
Schedule 4/2
Dose level 1, n = 5
Sunitinib
AUC0–24 (ng*h/mL) 1,166.8 (303.6) 1,020.4 (263.9) 0.88
Cmax (ng/mL) 60.1 (15.1) 51.9 (12.9) 0.87
Tmax (h)
a 8.0 (2.0, 8.0) 4.0 (4.0, 4.0) NA
SU12662
AUC0–24 (ng*h/mL) 341.9 (110.9) 366.8 (137.5) 1.06
Cmax (ng/mL) 16.3 (4.6) 17.7 (7.2) 1.05
Tmax (h)
a 6.0 (2.0, 12.0) 4.0 (1.0, 12.0) NA
Total drug
AUC0–24 (ng*h/mL) 1,508.9 (381.7) 1,387.4 (346.7) 0.92
Cmax (ng/mL) 75.6 (17.1) 69.5 (18.3) 0.91
Tmax (h)
a 8.0 (2.0, 8.0) 4.0 (4.0, 4.0) NA
Schedule 2/1
Dose level 3b
b,
n = 10
Sunitinib
AUC0–24 (ng*h/mL) 297.2 (89.0) 312.9 (88.4) 1.05
Cmax (ng/mL) 17.8 (5.9) 19.7 (7.4) 1.09
Tmax (h)
a 5.0 (4.0, 12.0) 7.0 (2.0, 12.0) NA
SU12662
AUC0–24 (ng*h/mL) 58.0 (22.3) 62.7 (32.4) 0.99
Cmax (ng/mL) 3.4 (1.3) 4.1 (1.9) 1.16
Tmax (h)
a 5.0 (4.0, 24.0) 7.0 (2.0, 24.0) NA
Total drug
AUC0–24 (ng*h/mL) 355.3 (105.5) 374.2 (103.7) 1.06
Cmax (ng/mL) 21.0 (7.0) 23.4 (8.9) 1.10
Tmax (h)
a 5.0 (4.0, 12.0) 8.0 (2.0, 24.0) NA
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123systemic therapy), small cell lung cancer (63-year-old
white female who had prior surgery and received carbo-
platin/etoposide and oxaliplatin/irinotecan as previous
systemic therapies), and NSCLC (62-year-old white female
who received carboplatin/gemcitabine as previous systemic
therapy). SD ([6 weeks) was observed in 12 (32%)
patients treated on Schedule 2/1, including 6 (43%) treated
at the MTD. PD was observed in 11 (29%) patients on
Schedule 2/1, including 7 (32%) of the patients treated at
MTD. Post-baseline measurements were not available for 5
patients, and response data were not evaluable for 7
patients.
Discussion
For many patients with solid tumors refractory to chemo-
therapy, therapeutic options are limited. Newer targeted
therapies, which may be given in combination with che-
motherapy, may offer a potential treatment approach [4,
19, 24, 25].
The primary objective of this phase I dose-ﬁnding study
was to assess the MTD and overall safety of sunitinib
administered on Schedules 4/2 or 2/1 in combination with
docetaxel for the treatment of subjects with advanced solid
tumors, including some who were heavily pre-treated and/
or had multiple metastases. This phase I study determined
the MTD as sunitinib 25 mg/day on Schedule 4/2 plus
docetaxel 60 mg/m
2 q21d (n = 4). The MTD was deter-
mined as sunitinib 37.5 mg/day plus docetaxel 75 mg/m
2
q21d (n = 23) on Schedule 2/1.
The safety proﬁle at MTD on Schedule 2/1 (sunitinib
37.5 mg/day plus docetaxel 75 mg/m
2 q21d) in this pop-
ulation of heavily pre-treated patients was acceptable with
aggressive management of hematologic toxicities. Most
toxicities were mild or moderate in severity (grade 1 or 2)
and similar in type to those previously reported with sun-
itinib and with docetaxel in patients with advanced solid
tumors [7, 19, 26]. The most common non-hematologic
toxicities were fatigue, diarrhea, and pyrexia. The observed
safety proﬁle was similar to that reported with this treat-
ment regimen (Schedule 2/1 sunitinib 37.5 mg/day, doce-
taxel 75 mg/m
2 q21d) in an exploratory analysis of patients
with breast cancer [27], as well as that reported following
administration of docetaxel [7]. In this breast cancer study
by Gianni et al. [27] the most commonly observed AE was
Table 6 continued
Mean (SD)
sunitinib alone
Mean (SD)
docetaxel ? sunitinib
Geometric mean ratio
(combination/drug alone)
(b) Docetaxel PK parameters
d
Schedule 4/2
Dose level 1, n = 5
Docetaxel
AUClast (ng*h/mL) 2,290.4 (596.1) 3,415.4 (1,102.8) 1.47
AUCinf (ng*h/mL) 2,552.7 (649.4) 3,692.8 (1,099.8) 1.43
Cmax (ng/mL) 2,100.0 (571.9) 3,098.0 (984.2) 1.46
t1/2 (h) 19.6 (10.6) 21.3 (7.4) NA
Tmax (h)
a 0.5 (0.5, 1.0) 0.5 (0.4, 1.0) NA
Schedule 2/1
Dose level 3b, n = 8
Docetaxel
AUClast (ng*h/mL) 2,712.5 (731.9) 3,056.5 (303.7) 1.16
AUCinf (ng*h/mL) 2,961.5 (766.6) 3,235.9 (298.5) 1.12
Cmax (ng/mL) 2,581.3 (535.6) 3,180.0 (495.5) 1.24
t1/2 (h) 15.7 (9.9) 17.7 (7.9) NA
Tmax (h)
a 0.6 (0.5, 1.0) 0.8 (0.5, 1.0) NA
Dose levels of sunitinib and docetaxel are detailed in Table 1
a For Tmax, median and range are reported
b 2/1 MTD = sunitinib 37.5 mg ? docetaxel 75 mg/m
2 q21d
c SU12662 is the primary metabolite of sunitinib
d Full PK proﬁles for sunitinib and SU12662 were obtained on days 18 and 22 on Schedule 4/2 and on day 3 of cycle 1, and day 1 of cycle 2 on
Schedule 2/1. PK proﬁles for docetaxel were obtained on days 1 and 22 of cycle 1 on Schedule 4/2 and on day 1 of cycles 1 and 2 on Schedule 2/1
NA Not applicable
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123severe neutropenia, which occurred at least once in all
patients. Neutropenia is commonly associated with doce-
taxel monotherapy; grade 3/4 neutropenia has been repor-
ted in 54–84% of patients in phase III trials of breast cancer
and NSCLC [28, 29]. The incidence of grade 3/4 febrile
neutropenia observed in this trial, although higher than
reported with single-agent docetaxel [28, 29], was man-
ageable with growth factor support. The sunitinib–doce-
taxel treatment combination appeared to be associated with
more common and more severe hematologic toxicity than
is typically observed with docetaxel or sunitinib alone [7,
30]. In this phase I trial, 13% of patients treated at Schedule
2/1 MTD experienced febrile neutropenia despite the use of
granulocytic growth factor support in 48% of patients. It is
noteworthy that use of granulocytic growth factor support
was substantially lower with single-agent docetaxel
(17.9%) compared with this study of sunitinib combined
with docetaxel [29].Given the limited number of patients in
this study, it is difﬁcult to identify the effects of the pos-
sible factors exacerbating neutropenia. While it is probable
that the neutropenia observed in this study may be related
to the heavily pre-treated nature of our patients and/or to
sunitinib treatment itself, determining a direct causality is
not possible. The manageability of the hematologic toxic-
ities with granulocytic growth factor support in this trial
contrasts some previous studies. For example, the phase III
trial evaluating sorafenib, carboplatin, and paclitaxel efﬁ-
cacy in NSCLC (ESCAPE) was terminated early due to
increased risk of mortality and toxicities, including higher
rates of grade 3/4 thrombocytopenia (14 vs. 6%) and febrile
neutropenia (5% vs.\3%) in patients treated with sorafe-
nib compared with chemotherapy alone [31]. Similarly, the
phase II/III trial of cediranib (30 mg/day or 45 mg/day),
carboplatin, and paclitaxel in patients with NSCLC was
terminated due to increased toxicities in the investigative
arm [32]. While c-Kit and FLT are important in hemato-
poiesis and may be key players in myelosuppression, their
potential off-target inhibition by sunitinib was not evalu-
ated in this study.
No patient experienced cardiac abnormalities, including
LVEF declines by C20% or to below the lower limit of
normal, suggesting that the combination does not lead to an
excessive risk for cardiac toxicity. Mean sunitinib and
docetaxel concentration data show overlapping PK proﬁles
during cycle 1 (docetaxel alone) and cycle 2 (docetaxel
plus sunitinib). Changes in PK parameters for docetaxel,
sunitinib, SU12662, and total drug at MTD on Schedule 2/
1 (37.5 mg/day sunitinib with 75 mg/m
2 docetaxel) are not
considered clinically relevant and indicate no PK drug–
drug interactions between sunitinib and docetaxel.
In summary, experience from our phase I trial demon-
strated that although 17% of patients treated at MTD
required sunitinib dose reductions and 13% developed
grade 3 or 4 febrile neutropenia, the heavily pre-treated
patients with advanced solid malignancies tolerated suniti-
nib on Schedule 2/1 in combination with docetaxel at rel-
evant doses of both agents. Therefore, the use of growth
factor support and the incidence of febrile neutropenia will
be evaluated closely in ongoing clinical trials of this treat-
ment combination to characterize more fully the hemato-
logic tolerability of this regimen. Ongoing clinical trials
include a phase III breast cancer trial comparing 37.5 mg
sunitinib on Schedule 2/1 plus docetaxel 75 mg/m
2 q21d
with docetaxel 100 mg/m
2 q21d alone, and a phase I/II trial
of sunitinib (12.5, 37.5, and 50 mg on Schedule 2/1) in
combination with docetaxel (60 and 75 mg/m
2) and pred-
nisone 5 mg twice daily for the ﬁrst-line treatment of
metastatic castrate-resistant prostate cancer. In the phase I
trial reported here, there were no clinically signiﬁcant drug–
drug interactions noted with either schedule, and although
efﬁcacy was not a primary endpoint of this trial, antitumor
data were suggestive of potential clinical beneﬁt.
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